Genmab announces expansion of collaboration with BioNTech.

NORDIC BUSINESS REPORT-August 5, 2022-Genmab announces expansion of collaboration with BioNTech

(C)2022 M2 COMMUNICATIONS http://www.m2.com

Danish biotechnology company Genmab A/S (Nasdaq:GMAB) (CPH:GMAB) and German biotechnology company BioNTech SE (Nasdaq:BNTX) announced on Friday an expansion of their global strategic collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients.

Under the expanded collaboration Genmab and BioNTech will jointly research, develop and commercialize, subject to regulatory approval, monospecific antibody candidate GEN1053/BNT313 leveraging Genmab's proprietary HexaBody technology platform. The companies will equally share the development costs and potential future profit deriving from GEN1053/BNT313.

GEN1053/BNT313, is a CD27 antibody based on the HexaBody technology, specifically engineered to form an antibody hexamer (a formation of six antibodies) upon binding its target on the cell membrane of...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT